Safety and Efficacy of Obatoclax Mesylate (GX15-070MS)for the Treatment of Myelodysplastic Syndromes (MDS)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Teva Pharmaceutical Industries ( Gemin X )
ClinicalTrials.gov Identifier:
NCT00413114
First received: December 18, 2006
Last updated: August 16, 2013
Last verified: August 2013
  Purpose

Defects in the apoptotic process can lead to the onset of cancer by allowing cells to grow unchecked when an oncogeneic signal is present. Obatoclax is designed to restore apoptosis through inhibition of the Bcl-2 family of proteins, thereby reinstating the natural process of cell death that is often inhibited in cancer cells.

This is a multi-center, open-label, Phase II study of obatoclax administered in 2-week cycles to patients with previously-untreated Myelodysplastic Syndromes with anemia and/or thrombocytopenia. Treatment may be administered on an outpatient basis. No investigational or commercial agents or therapies other than those described herein may be administered with the intent to treat the patient's malignancy. Supportive care measures including those directed at controlling symptoms resulting from Myelodysplastic Syndromes are allowed


Condition Intervention Phase
Myelodysplastic Syndromes
Drug: Obatoclax mesylate (GX15-070MS)
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II Study of Obatoclax Mesylate (GX15-070MS) in Patients With Previously-Untreated Myelodysplastic Syndromes (MDS) With Anemia and/or Thrombocytopenia

Resource links provided by NLM:


Further study details as provided by Teva Pharmaceutical Industries:

Primary Outcome Measures:
  • International Working Group (IWG) Response Criteria for MDS [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]
    Determine the response rate according to bone marrow blast count less than or equal to 10%


Secondary Outcome Measures:
  • Peripheral blood counts; Bone marrow aspirates and biopsies; Transfusions and growth factor requirements [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]
    hemoglobin level less than 10 g/dL and or platelets less than 50 x 10 9/L. Eastern Cooperative Onocology Group (ECOG) performance status: 0 fully active-2 ambulatory 50% of the time; and total bilirubin less than or equal to 2 mg/dL; normal limits of SGOT/SGPT and creatinine according to laboratory standards


Enrollment: 24
Study Start Date: December 2006
Study Completion Date: November 2009
Primary Completion Date: February 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Obatoclax Mesylate
Obatoclax Mesylate 30mg
Drug: Obatoclax mesylate (GX15-070MS)

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Pathological confirmation of Myelodysplastic Syndromes (MDS)
  • Patients must have had no prior systemic therapy
  • Must have normal organ functions
  • Must have the ability to understand and willingness to sign a written informed consent form

Exclusion Criteria:

  • Must not be a result of prior chemotherapy and/or radiotherapy for another malignancy
  • No other agents or therapies administered in the intent to treat
  • Uncontrolled, intercurrent illness
  • Pregnant women and women who are breast feeding
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00413114

  Hide Study Locations
Locations
United States, California
Stanford University
Stanford, California, United States, 00000
United States, District of Columbia
Georgetown University Medical Center
Washington, District of Columbia, United States, 20007
United States, Florida
James A. Haley Veterans Hospital
Tampa, Florida, United States, 33612
United States, Georgia
Emory University School of Medicine/ Winship Cancer Center
Atlanta, Georgia, United States, 30322
Northwest Georgia Oncology Centers
Marietta, Georgia, United States, 30060
United States, Illinois
University of Chicago
Chicago, Illinois, United States, 60637
United States, Massachusetts
University of Massachusetts Medical Center
Worcester, Massachusetts, United States, 01605
United States, Michigan
Michigan State University, Breslin Cancer Center CTO
Lansing, Michigan, United States, 48910
United States, Montana
Hematology-Oncology Centers of the Northern Rockies
Billings, Montana, United States, 59101
United States, New York
St. Vincent's Comprehensive Cancer Center
New York, New York, United States, 01605
United States, Oregon
Pacific Oncology
Portland, Oregon, United States, 97210
United States, Tennessee
The West Clinic
Memphis, Tennessee, United States, 38120
Sarah Cannon Cancer Research Institute
Nashville, Tennessee, United States, 37203
United States, Texas
Arlington Cancer Center
Arlington, Texas, United States, 76012
Texax Oncology, P.A., Presbyterian/ Mary Crowley Clinical Research Centers
Dallas, Texas, United States, 75231
Mary Crowley Medical Research Center
Dallas, Texas, United States, 75246
MD Anderson Cancer Center (Protocol 2006-0688)
Houston, Texas, United States, 77030
Canada, Alberta
Tom Baker Cancer Centre
Calgary, Alberta, Canada
Canada, Nova Scotia
QEII HSC
Halifax, Nova Scotia, Canada, B3H 2Y9
Canada, Ontario
Princess Margaret Hospital
Toronto, Ontario, Canada, M5G 2M9
Canada, Quebec
Hospital Notre-Dame du Chum
Montreal, Quebec, Canada, H2L4M1
Maisonneuve-Rosemont Hospital
Montreal, Quebec, Canada
Sponsors and Collaborators
Gemin X
Investigators
Study Director: Mark Berger, MD Gemin X, Inc.
  More Information

No publications provided

Responsible Party: Teva Pharmaceutical Industries ( Gemin X )
ClinicalTrials.gov Identifier: NCT00413114     History of Changes
Other Study ID Numbers: GEM013
Study First Received: December 18, 2006
Last Updated: August 16, 2013
Health Authority: United States: Food and Drug Administration
Canada: Health Canada

Additional relevant MeSH terms:
Myelodysplastic Syndromes
Preleukemia
Bone Marrow Diseases
Hematologic Diseases
Precancerous Conditions
Neoplasms

ClinicalTrials.gov processed this record on July 20, 2014